



Updated Monthly

February 11, 2026

Prepared for:



THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:



Questions?

Liz Powell, Esq., MPH

lpowell@G2Gconsulting.com

www.G2Gconsulting.com

  @G2Gconsulting





GBG Report

Updated Monthly

February 11, 2026

<https://www.g2gconsulting.com/gbg-reporting-service/>

TABLE OF CONTENTS

New Opportunities

Aging.....	2
Biomedical Research.....	3
Cancer.....	4
Cardiovascular and Pulmonary Health.....	4
Cognitive and Brain Health.....	5
Communication Disorders.....	5
Endocrine & Metabolic Disease	6
Food Security	6
Genomics.....	7
Health IT & Data.....	7
HIV/AIDS	8
Immunology & Infectious Disease	8
Medical Countermeasures.....	9
Musculoskeletal Health	10
Precision Medicine.....	10
Substance Use Disorder	11
Therapeutics.....	11
Veterinary Medicine.....	11
Women's Health.....	11

Recurring Opportunities

Advanced Research Projects Agency for Health.....	13
Air Force	14
Army.....	15
BARDA	17
DARPA	17
Defense Threat Reduction Agency	18
Department of Energy.....	19
Navy	19
Office of the Undersecretary of Defense	19
Patient-Centered Outcomes Research Institute	20
GBG Acronyms	22



February 19, 2026 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EST (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you’re an affiliate of Biocom, BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Life Sciences Association, Georgia Life Sciences, IowaBio, MichBio, NCBiotech, NMBio, Ohio Life Sciences, South Dakota Biotech, VaBio, or BioWV – your membership gets you access to the [private consultation meeting](#).

Military Health System Research Symposium – Did you miss G2G’s annual MHSRS prep webinar? [Watch it now!](#)

Women’s Health Advocates– Catch up with the WHA Community at one of their [upcoming events!](#) Meet G2G Founder Liz Powell at a [movie screening in Boston on February 26](#), or reach out to attend the WHA Endo & Adeno Coalition’s Hill Day on March 10.

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING (5)		
1.	Forecast: Specialized Center and Resource-Related Research Projects Cooperative Agreements in Aging and/or AD/ADRD Research (NIH/NIA) PAR-25-461 (U54) PAR-25-462 (U24)	These NOFOs will support large-scale, complex research programs focused on aging and/or AD/ADRD research. It is anticipated that such programs will likely involve a team of investigators from a single institution, or a consortium of institutions, and align with the mission and research priorities of NIA. https://www.grants.gov/search-results-detail/361170 (U54) https://www.grants.gov/search-results-detail/361185 (U24)	TBD	Estimated post date: 4/25/26 Estimated proposal date: 6/26/26
2.	Forecast: Controlled Clinical Trials on Long-Term Effects of Nutritional Interventions on the Progression of Risk Factors for Age-Related Chronic Conditions Over the Life Span and Their Age of Onset (NIH/NIA) PAR-26-065	This NOFO will solicit applications for randomized controlled clinical trials on long-term effects of nutritional interventions on the progression of risk factors for age-related chronic conditions over the life span and their age of onset. Although considerable information is available on health benefits and risks of a variety of nutritional factors, there remains a need for better understanding of long-term benefits and potential risks of differing nutritional factors and dietary practices to maintain health across the full range of the life span. https://www.grants.gov/search-results-detail/361214	TBD	Estimated post date: 6/25/26 Estimated proposal date: 9/25/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING		
3.	Forecast: NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurship Enhancement Award (NIH/NIA) PAR-26-066	The goal of the program is to prepare trainees for a wide-range of career paths, including those that are outside the traditional research environment. As such, NIA is seeking applications proposing innovation-focused programs that are geared towards imparting a broad set of skills and knowledge required for a career in translational sciences and entrepreneurship in order to boost the number of Ph.D.-trained scientists prepared and ready for a multitude of available career options. https://www.grants.gov/search-results-detail/361215	TBD	Estimated post date: 7/24/26 Estimated proposal date: 9/25/26
4.	Forecast: Research Project Cooperative Agreements in Aging and/or AD/ADRD Research (NIH/NIA) PAR-26-094	This NOFO will solicit applications for research project cooperative agreements. Areas of research that fall within NIA's mission include: genetic, biological, neuroscientific, preclinical, clinical, behavioral, social, psychological, and economic research on aging and the health and well-being of older people. https://www.grants.gov/search-results-detail/361168	Dependent upon proposal, for up to 7 years	Estimated post date: 4/20/26 Estimated proposal date: 6/20/26
		BIOMEDICAL RESEARCH (3)		
5.	NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional) (NIH) PA-26-002	This NOFO supports international research collaborations. This opportunity specifically implements an award structure of prime domestic awards with independent foreign awards that are linked to the prime. This structure provides NIH with oversight capacity for international collaborations, and allows NIH to track international funding. https://www.grants.gov/search-results-detail/360581	Dependent upon proposal, for up to 7 years	Multiple deadlines; NOFO open through 1/25/29
6.	National Centers for Cryo-electron Tomography (cryoET) (R24 -Clinical Trial Not Allowed) (NIH/NIGMS) PAR-26-138	This program will support service centers for nationwide access to state-of-the-art cryoET technology, expertise, and training. A goal of this program is to increase national expertise in cryoET; service centers will therefore prioritize training users to work independently rather than focusing on only providing user service. https://www.grants.gov/search-results-detail/359656	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 1/26/27
7.	Complement-ARIE NAMs Reduction to Practice Challenge (NASA)	This challenge invites innovative combinatorial NAMs solutions from multidisciplinary teams who can successfully demonstrate implementation of their human-based solution in a practical and usable form within a 3-year period. Priority areas include: Chronicity, Neurobiological Models; Personalized Medicine; Cross-Disease Pathogenesis; Toxicology and Safety; and Human Health Protection. https://www.herox.com/Complement-ARIE-RTP	Up to \$1.43 million, over 3 years	Proposal: 3/1/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER (6)		
8.	The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed) (NIH/NCI) PAR-26-134	NCI is soliciting applications proposing research projects that use integrative systems-level approaches to address a specific question in metastasis research. Such projects are expected to integrate with the NCI's MetNet and complement its ongoing research. Proposed projects should emphasize one of the central themes defined in the MetNet NOFO (RFA-CA-20-029) such as dormancy, early dissemination, cellular and/or physical microenvironment crosstalk, or mechanisms of responses by metastatic cells to therapies. https://www.grants.gov/search-results-detail/359725	Up to \$500,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 11/5/28
9.	Forecast: FY26 Breast Cancer Research Program (DoD/CDMRP)	Five awards are anticipated: Breakthrough Award (four funding levels); Era of Hope Scholar Award; Clinical Research Extension Award; Transformative Breast Cancer Consortium Award; and Transformative Breast Cancer Consortium Development Award. All applications must address one or more of the overarching challenges . https://cdmrp.health.mil/pubs/press/2026/bcrppreann	Up to \$35 million, for up to 4 years Dependent upon award mechanism	TBD
		CARDIOVASCULAR AND PULMONARY HEALTH (2)		
10.	Agentic AI-Enabled CardioVascular CAre TransfOrmation (ADVOCATE) (ARPA-H) ARPA-H-SOL-26-142	ADVOCATE will support the development of clinical AI agents that can be trusted to autonomously adjust changes in appointments, medications, diet, and exercise. In parallel, ADVOCATE will support the development of a supervisory AI "overseer" to monitor clinical AI agents after they have been deployed in clinical practice to ensure their continued safety and efficacy. https://sam.gov/workspace/contract/opp/76c173daa18b46fba61c5297e4a56140/view	Dependent upon proposal and award mechanism	Solution Summary: 2/27/26 Proposal: 4/1/26
11.	Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways (EU) HORIZON-HLTH-2026-01-DISEASE-11	Proposals should address most of the following aspects: Contribute to further the understanding on the structural, hormonal, and/or biological distinctions between sexes/genders to improve diagnostics and therapeutics for CVDs; Develop sex and/or gender-specific tailored risk models in a view of better prevention, detection and diagnostic, and treatment strategies; Identify and/or validate novel or existing sex and/or gender-specific health determinants, risk factors and pathways for cardiovascular disease(s) through the generation, integration and validation of data derived from relevant disciplines; Make use of existing health data, including registries or cohorts, and/or assess the necessity to establish new ones, as well as, where relevant, exploit the knowledge gained from population-based biobanks. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2026-01-DISEASE-11	Total funding of €38 million	Proposal: 4/16/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH (3)		
12.	Forecast: BRAIN Initiative: Brain-Behavior Quantification and Synchronization – Transformative Research on Behavior at the Organismal Level (NIH) RFA-DA-27-011	The BRAIN Initiative's BBQS Program supports the development of tools for high-resolution, multimodal tracking of complex behaviors synchronously with neural activity and advancement of theoretical frameworks and computational models for understanding neurobehavioral function in real-world settings. This BRAIN Initiative-funded BBQS opportunity will support transdisciplinary research involving human subjects and/or other species aiming to advance methods to capture and model complex behavior at the organismal level in dynamic environments. https://www.grants.gov/search-results-detail/361205	Total funding of \$8 million	Estimated post date: 6/25/26 Estimated proposal date: 10/13/26
13.	The NINDS Human Biospecimen and Data Repository (U24 - Clinical Trial Not Allowed) (NIH/NINDS) RFA-NS-26-010	This open competition NOFO requests applications from organizations to serve as an integrated and comprehensive biospecimen resource for the NINDS. The repository will manage the existing collection and expand the collection to bank well-annotated high-quality clinical biospecimens to foster discovery and validation of neurological biomarkers as well as complementary basic, translational, and clinical research. https://www.grants.gov/search-results-detail/358861	Up to \$1.95 million per year, for up to 5 years	Proposal: 3/9/26
14.	BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed) (NIH) RFA-NS-27-001	The overall goal of this NOFO is to accelerate the scientific impact of the BRAIN Initiative through rapid dissemination of developed and validated technologies and resources broadly to the neuroscience research community. This NOFO will support applications which address one or more of the specific goals of the BRAIN Initiative, as described in the planning document "BRAIN 2025: A Scientific Vision" and updated and enhanced in 2019 by "The BRAIN Initiative 2.0: From Cells to Circuits, Toward Cures". https://www.grants.gov/search-results-detail/358859	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 10/6/28
		COMMUNICATION DISORDERS (3)		
15.	Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional) (NIH/NIDCD) RFA-DC-26-001	NIDCD invites applications for early-stage dissemination and implementation (D&I) research projects (e.g., during development and evaluation of the evidence-based innovation, EBI) in the NIDCD mission areas of hearing, balance, taste, smell, voice, speech, and language. https://www.grants.gov/search-results-detail/359274	Up to \$275,000, for up to 2 years	Multiple deadlines; NOFO open through 6/17/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COMMUNICATION DISORDERS		
16.	Forecast: National Resource Network for the Study of Human Auditory and Vestibular Disorders (NIH/NIDCD) RFA-DC-27-001	In collaboration with NIDCD and other Network laboratories, each laboratory is anticipated to advance the use of human ear tissue in biomedical research by developing and providing technical services for procuring, preparing, sectioning and distributing high-quality human ear tissues; developing and disseminating techniques for improved tissue preservation and processing; uploading digitized temporal bone images to NIDCD-approved databases for wide dissemination; and providing opportunities for technical instruction in the special skills needed to prepare ear tissue for use from post-mortem human temporal bones. https://www.grants.gov/search-results-detail/361207	Up to \$450,000	Estimated post date: 3/7/26 Estimated proposal date: 9/29/26
17.	Forecast: Coordinating Center for National Resource Network for the Study of Human Auditory and Vestibular Disorders (NIH/NIDCD) RFA-DC-27-002	The National Human Ear Resource Network is a critical national technological resource for auditory and vestibular researchers who use human inner and middle ear tissues for a range of basic and clinical studies. The Network serves as a nucleus for expanding the use of human temporal bones in the research community and facilitates communication and collaboration between laboratories that utilize human temporal bones in their research. https://www.grants.gov/search-results-detail/361208	Up to \$100,000	Estimated post date: 3/7/26 Estimated proposal date: 9/29/26
		ENDOCRINE & METABOLIC DISEASE (1)		
18.	Forecast: Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research (NIH/NIDDK) RFA-DK-27-140	The main goal of this initiative is to establish a consortium with the overarching goal to advance the systematic identification, rigorous evaluation, validation, and assays harmonization of biomarkers that are critical to the prevention, diagnosis, and clinical management of T1D. Despite significant advances in T1D research, there remains an urgent need for reliable and reproducible biomarkers that can capture the complexity of autoimmune processes, metabolic dysregulation, and individual patient variability. https://www.grants.gov/search-results-detail/361235	Total funding of \$5.2 million	Estimated post date: 4/1/26 Estimated proposal date: 6/25/26
		FOOD SECURITY (1)		
19.	BARD Food Security Technology Accelerator (BARD)	BARD is seeking collaborative research and development projects that aim to generate innovative solutions to critical challenges in global food security. This pilot program is designed to accelerate the development and implementation of advanced, sustainable, and scalable technologies and practices. Research themes are: Climate Resilience; Crop and Animal Health; and AI-powered precision farming and digital agriculture. https://www.bard-isus.org/news/call-for-proposals/	Up to \$1 million, for up to 3 years Applicants must be consortium of research institutions and companies from Israel and the US.	Pre-Proposal: 3/31/26 Full proposal: 6/25/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		GENOMICS (2)		
20.	Forecast: Discovery of the Genetic Basis of Childhood Cancers and of Congenital Anomalies: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) (NIH) PAR-26-107	NIH will invite applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First Program supported sequencing center. Applicants are encouraged to propose sequencing of existing cohorts of pediatric cancer or congenital anomalies to elucidate the genetic contribution (somatic and/or germline) to childhood cancers, to investigate the genetic etiology of congenital anomalies, to study the molecular basis of the associations between congenital anomalies and increased cancer risk, or to expand the range of pediatric disorders included within the Kids First Data Resource. https://www.grants.gov/search-results-detail/361164	Resource support only (X01)	Estimated post date: 5/19/26 Estimated proposal date: 7/19/26
21.	Forecast: Genomic Community Resources (U24 Clinical Trials Not Allowed) (NIH/NHGRI) RFA-HG-26-002	This NOFO will support both new and existing genomic resources of demonstrated broad value to the research community. Awards under this NOFO will support the development, curation, and distribution of high-value genomic resources valuable for both basic and clinical genomics research. https://www.grants.gov/search-results-detail/361263	Total funding of \$30 million	Estimated post date: 9/25/26 Estimated proposal date: 1/25/27
		HEALTH IT & DATA (2)		
22.	Building Sustainable Software Tools for Open Science (R03 Clinical Trial Not Allowed) (NIH) RFA-OD-26-034	This funding opportunity is intended to provide a flexible mechanism to support the use of best practices and design principles for scientific software development/engineering and to promote community engagement for open science. Successful grants will enable and/or enhance biomedical, clinical, behavioral, social, and health-related research endeavors by (1) developing robust, sustainable, scalable, and reproducible research software tools and workflows, (2) extending the impact of research software by broader dissemination to the scientific community, (3) supporting collaborations between scientists and software engineers to leverage modern, best practices in research software development, and (4) enhancing software skills of the research workforce. https://www.grants.gov/search-results-detail/361239	TBD	Estimated post date: 4/15/26 Estimated proposal date: 6/16/26
23.	Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed) (NIH Common Fund) RFA-RM-26-017	The goals of this NOFO are to 1) promote the use of Common Fund data sets by supporting pilot studies based on analyses across two or more Common Fund data sets; 2) enhance the utility of existing Common Fund data sets by developing workflows, analytic and simulation tools which will enable simultaneous analysis of multiple Common Fund data sets; and 3) demonstrate the added-value of integrating multiple Common Fund data resources in addressing biomedical research questions. https://www.grants.gov/search-results-detail/359879	Up to \$200,000, for up to 1 year	Proposal: 6/23/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS (2)		
24.	Forecast: Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Intervention and Services Research Trials (NIH/NIDA) PAR-26-092	NIDA seeks to support pilot and feasibility studies in preparation for efficacy, effectiveness and/or services research trials. Topics may include:1) developing interventions to prevent substance use, misuse or progression to disorder, 2) substance use prevention, treatment or recovery services research, including comorbid pain, medical and mental health disorders, 3) HIV eradication research, including implementation science, prevention, treatment and recovery in substance use settings/populations. https://www.grants.gov/search-results-detail/361204	TBD	Estimated post date: 7/2/26 Estimated proposal date: 10/2/26
25.	Forecast: ORACLE 3C: Chronic Conditions, Coinfections, and Comorbidities in HIV (NIH/NICHD) PAR-26-105	HIV-related 3Cs cause significant and different pathology in people with and without HIV. Development of preventive and therapeutic strategies based on understanding HIV-specific pathways and mechanisms, and implementing those strategies is critical, especially in pediatric and maternal populations. A pipeline of innovative researchers from other fields of research including mathematics, engineering, computer science, and AI will bring new ideas and innovative approaches. https://www.grants.gov/search-results-detail/361255	Total funding of \$1.96 million	Estimated post date: 7/24/26 Estimated proposal date: 9/25/26
		IMMUNOLOGY & INFECTIOUS DISEASE (4)		
26.	Development of Susceptibility Test Interpretive Criteria (STIC or Breakpoints) for Candida auris (FDA) FDABAA-26-00123	The FDA has released a topic call for their FY26 Regulatory Science BAA. Research proposals focused on evaluating microbiologic and pharmacokinetic data that could be utilized by standards development organizations and the FDA to update susceptibility test interpretive criteria (breakpoints) will be prioritized. FDA is interested in advancing the science of drug susceptibility testing in the treatment of <i>C. auris</i> infections. https://www.fda.gov/media/190984/download	Dependent upon proposal and award mechanism	Proposal: 2/24/26
27.	Development of novel vaccines for viral pathogens with epidemic potential (EU) HORIZON-HLTH-2026-01-DISEASE-04	Applicants should target only one specific virus. The proposed work should aim to advance the development of existing prophylactic and therapeutic vaccine candidates targeting exclusively one of the following viruses: Junin mammarenavirus; Lassa mammarenavirus; Andes virus; Hantaan virus; Sin Nombre virus; Hendra virus; Enterovirus D68; Venezuelan equine encephalitis virus. Proposals should thus aim to diversify and accelerate the global prophylactic and therapeutic research and development portfolio for emerging and re-emerging viral infections, and to strengthen the leading role of the EU in prophylactic and therapeutic research and development. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2026-01-DISEASE-04	Total funding of €44.2 million	Proposal: 4/16/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
28.	Impact of Initial Influenza Exposure on Immunity in Infants (U01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-27-019	This NOFO supports the establishment or continuation of longitudinal infant cohorts to determine and compare how initial and repeated natural influenza infections and/or influenza vaccinations shape infant and childhood immunity to future influenza exposures. The goal of this research is to understand how these exposures influence immune responses to subsequent influenza infections and/or vaccines and provide key information to facilitate design of durable, broadly protective influenza vaccines. https://www.grants.gov/search-results-detail/359939	Up to \$3 million per year, for up to 5 years	Proposal: 6/4/26
29.	SMART Antiviral Prize (BARDA/VITAL)	The goal of this competition is to advance the development of novel antivirals that strengthen the therapeutic pipeline and address gaps in strategic preparedness in partnership with innovators offering creative solutions. The SMART Antiviral Prize focuses on supporting the development of antivirals with broad-spectrum activity against members of the Togaviridae and/or Flaviviridae families. https://vitalhubhealth.com/smart-antiviral-prize/	\$2.5 million (Concept Stage) \$6 million (Stage 1)	Proposal: 5/11/26
		MEDICAL COUNTERMEASURES (4)		
30.	Production of Drug Substances and Drug Products at Commercial Scale – Anti-Microbials and Large Volume Parenterals (BARDA/BioMaP) 26-2-AM-LVP	ASPR IBMSC is seeking to develop a drug substance and drug product manufacturing design-build-test cycle at a scale that demonstrates the ability to produce hundreds of millions of doses of drug substances to support the American public (population scale), with a focus of sustaining domestic production capacities. HHS DPA Title III Program is interested in submissions that strengthen the Nation’s security of supply for at least one (1) key starting material (KSM), drug substance, and/or drug product identified within the FDA’s List of Essential Medicines, with a preference for submissions that focus on Anti-Microbials and Large Volume Parenterals. https://www.biomap-consortium.org/solicitation/request-for-project-proposals-production-of-drug-substances-and-drug-products-at-commercial-scale-anti-microbials-and-large-volume-parenterals/	Total funding of \$200 million, for up to 2 years	Enhanced white paper: 3/9/26
31.	Development of Radiological/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices (NIH/NIAID) BAA-75N93026R00004	The goals of this BAA are two-fold. The first goal is to support the development of safe and effective MCMs to mitigate and/or treat normal tissue injuries arising from exposure to ionizing radiation from a radiological or nuclear incident, thereby leading to a reduction in radiation-associated mortality and/or major morbidities. The second goal is to support advancement of biodosimetry biomarkers and/or devices to inform triage and treatment strategies for use during a radiation public health emergency. https://sam.gov/workspace/contract/opp/do7b8056bd464052bedaa23fd577dfoe/view	Dependent upon contract	Proposal: 5/4/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MEDICAL COUNTERMEASURES		
32.	Protean (DoD/DARPA) DARPA-SN-26-38	The Protean program is working to render chemical weapons ineffective by prophylactic medicines that neutralize the threat at the molecular level. Current approaches focus on treating the symptoms of exposure or attempting to intercept the chemical before it reaches its target. Protean, however, aims to stop the poisoning at its source by engineering resilience into the very proteins that are targeted by these chemicals. This groundbreaking approach involves mapping the rapid, dynamic movements of key proteins in the body and designing interventions that restore their normal function even in the presence of toxic agents. https://sam.gov/opp/54b72106d3f44755a95c3ed8ff4552c8/view	TBD	Proposers' Day: 2/20/26
33.	Market Research: Stabilization Technologies for CBRN Medical Countermeasures (BARDA/BioMaP)	The BARDA CBRN Division seeks input from industry regarding stabilization approaches that may: Extend the shelf life of CBRN MCMs; Reduce or eliminate frozen or ultra-cold chain storage requirements; and/or Improve long-term stockpile sustainment and logistical flexibility. Approaches of interest may include, but are not limited to, formulation-based methods; physical state modifications; encapsulation or matrix-based platforms; and novel excipient, stabilizer, or carrier systems. https://www.biomap-consortium.org/solicitation/market-research-stabilization-technologies-for-cbrn-medical-countermeasures/	N/A	Response: 2/19/26
		MUSCULOSKELETAL HEALTH (1)		
34.	Forecast: Restoring Joint Health and Function to Reduce Pain (RE-JOIN) 2.0 (NIH/NIAMS) RFA-AR-26-006	The NOFO aims to more fully refine and map the innervation of the different articular and peri-articular tissues that collectively form the joint (including bone, cartilage, synovium, joint capsule, ligament, tendon, fascia and muscle), by sensory neurons that mediate the sensation of pain. https://www.grants.gov/search-results-detail/361186	TBD	Estimated post date: 10/1/26 Estimated proposal date: 12/1/26
		PRECISION MEDICINE (1)		
35.	Forecast: Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (NIH) PAR-26-127	The All of Us Research Program seeks to advance its mission by enabling access to biospecimens stored in the All of Us supported Biobank for researchers to conduct assays to evaluate associations between biomarkers and chronic diseases and add data to the All of Us resource for broad use by researchers. Biomarker analysis includes, but is not limited to, biomarker discovery; biomarker validation; novel disease stratification; and multiomics integration for disease risk, diagnosis, and prognosis, in support of advancing precision medicine. https://www.grants.gov/search-results-detail/361104	TBD	Estimated post date: 4/1/26 Estimated proposal date: 6/1/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER (1)		
36.	Forecast: Specialized Alcohol Research Centers (P50 Clinical trial Optional) (NIH/NIAAA) RFA-AA-27-001	The focus of the NIAAA Centers program should be on generating a critical mass of researchers in a given understudied and/or innovative topic area relevant to the NIAAA mission with an emphasis on interdisciplinary coordination and cooperation among independent researchers and development and mentorship of young investigators. Topics include but are not limited to, the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol misuse, AUD, alcohol-related end-organ diseases, and their biomedical, psychosocial, and economic consequences across the lifespan. https://www.grants.gov/search-results-detail/361216	TBD	Estimated post date: 5/15/26 Estimated proposal date: 9/15/26
		THERAPEUTICS (1)		
37.	BIOMolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI) (ARPA-H) ARPA-H-SOL-26-149	The BIOGAMI program aims to stop diseases like Alzheimer's and other brain disorders by finding and fixing problems with proteins very early—before they clump together and damage cells The program has two technical focus areas: (1) build next-generation artificial intelligence and experimental models for intrinsically disordered proteins (IDPs) and aggregation; and (2) leverage novel tools to develop novel therapeutic modalities that interfere with or prevent IDP misfolding and aggregation while preserving critical functions, and create novel detection capabilities that respond to early-stage IDP aggregation. https://sam.gov/workspace/contract/opp/23802b14ac3d4c79bd67c6cac7e06db5/view	Dependent upon proposal and award mechanism	Proposers' Day: 2/20/26 Solution Summary: 3/4/26 Proposal: 4/15/26
		VETERINARY MEDICINE (1)		
38.	New World Screwworm Grand Challenge (USDA/APHIS) USDA-APHIS-10025-OA000000-26-0001	APHIS will support projects that enhance sterile NWS fly production, develop novel NWS traps and lures, develop and increase understanding of NWS therapeutics/treatments in animals, or develop other tools to bolster preparedness or response to NWS. APHIS will support projects that: Enhance sterile NWS fly production; Develop novel NWS traps and lures; Develop and increase understanding of NWS therapeutic/treatments for animals; or Develop other tools to bolster preparedness or response to NWS. https://www.grants.gov/search-results-detail/361182	Up to \$5 million	Proposal: 2/23/26
		WOMEN'S HEALTH (3)		
39.	CIF Catalytic Innovation Prize at CURE Power of X (CIF/Cure)	This pitch competition for women's health startups is: Open to companies addressing a disease or condition that affects women exclusively, disproportionately or differently. Company must be raising Pre-Seed through Series A funding, and must be (or will be) a C-Corp or B-Corp. Finalists must be present in person in NYC on March 18th to present. https://airtable.com/appRNYgu7lkAqXi52/pag8ltoGPSsbxzbvS/form	Equity investment of \$50,000-\$100,000	Proposal: 2/23/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		WOMEN'S HEALTH		
40.	2026 \$200K Challenge (M2D2)	<p>Areas of interest include: Devices intended to simplify and improve women's health, using the definition of women's health as conditions that only affect women, affect women disproportionately, or affect women differently. Of particular interest are therapeutic procedures, especially minimally invasive in both OR and office sites of service, or of use in low and middle income (LMIC) areas of the world, filling treatment gaps and advancing patient care. Focus areas include: Uterine Health; Pelvic Health; Maternal & Perinatal Health Equity (Rural Focus); Oncology impacting women; Breast Health; Point of Care opportunities in diagnostics; Non-surgical visualization.</p> <p>https://m2d2challenge.com/200k-challenge</p>	\$200,000 in in-kind services, strategic support, and cash awards	Proposal: 2/15/26
41.	VISIBLE: Women's heart disease revealed (Wellcome/Pivotal)	<p>The goal of VISIBLE is to increase the proportion of women presenting with stable angina who receive effective diagnosis and treatment for coronary microvascular disease from less than 1% to more than 80%, without increasing the risk of missed diagnosis or treatment of obstructive coronary artery disease. In so doing, the program aims to demonstrate advances capable of reducing the burden of cardiovascular disease for millions of women worldwide.</p> <p>https://wellcomeleap.org/visible/</p>	Total funding of \$55 million	Abstract: 3/9/26 Proposal: 4/23/26





Recurring Opportunities

February 11, 2026

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)		
42.	Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-103	RSO is interested in innovations that take a systems level approach in areas including, but not limited to, systems biology, data systems, biophysical systems, health IT systems, sociotechnical systems, health-related systems engineering, and other systems with the potential to improve health outcomes. https://sam.gov/workspace/contract/opp/36eb58892e1f49f897c81d87ff7a95fe/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
43.	Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems. https://sam.gov/workspace/contract/opp/29c3ac2ea6754d1f897f9c71204c0eea/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
44.	Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, also flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Advanced Technologies for Medical Product and Capability Distribution; and Biomanufacturing Innovations. https://sam.gov/workspace/contract/opp/c79dfo57a7e44d2cb3072e4ce3307422/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
45.	Proactive Health Office (PHO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes. https://sam.gov/workspace/contract/opp/a5b72db5139040f8b2a1dcc2d2c96733/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (4)		
46.	Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS) FA238424S2233	CHEERS MAA is intended to provide a comprehensive strategy for AFRL/RH and USAFSAM's range of S&T, allowing for progression from basic research to technology maturation and transition. Areas of interest include: Aerospace Medicine and Physiology; Public Health and Preventative Medicine; Occupational Medicine and Bioenvironmental Engineering; and En Route Care/Expeditionary Medicine/Prolonged Field Care. https://sam.gov/opp/4caa8d320fb24050b389fe721296a13d/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis
47.	AFRL/RX Functional Materials Open BAA FA8650-22-S-5002	The Functional Material Open BAA seeks to exploit innovative functional materials that enable new warfighting capabilities, significantly improve the effectiveness of warfighters and their current and future systems and solve urgent operational needs. The Biomaterials Materials and Processes (BM&P) Research area seeks to accelerate materials development, protect assets from the environment, and enable airman performance. This research area harnesses materials and processes competencies in soft matter materials characterization, molecular and synthetic biology, microbiology, biochemistry, bioinformatics, machine learning, multiscale modeling, bioelectronics, bio- functionalization, and biological engineering to create materials not easily achievable through traditional chemical synthesis or additive manufacturing. https://sam.gov/opp/2fad41c2700409c993a8c308c6f5120/view	Dependent upon proposal and award mechanism	White paper: 10/28/28
48.	Research Interests of the Air Force Office of Scientific Research FA9550-25-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Chemistry and Biological Sciences Team is responsible for research activities in chemistry and biological sciences. The focus is on complex materials, microsystems and structures and well as systems of a biological natural by incorporating hierarchical design of mechanical and functional properties from the nanoscale through the mesoscale, ultimately leading to controlled well- understood chemistry/biochemistry, and material or structural behavior capable of dynamic functionality and/or performance characteristics to enhance mission versatility. https://www.grants.gov/search-results-detail/359050	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
49.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY (10)		
50.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29
51.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
52.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
53.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
54.	Medical CDID BAA MED CDID	MED CDID invites innovative proposals that allow future Army medical units to efficiently and effectively clear the battlefield (evacuation of wounded, ill, and injured), maximize return to duty, and overcome contested logistics (medical resupply). https://vulcan-sof.com/login/ng2/submission?collectionUuid=5417cc3c-2b60-446a-addf-cobe38cd0b1	Dependent upon proposal	White papers accepted through 12/31/2030



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
55.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; view the full list of research topics . https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
56.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
57.	Army Applications Lab BAA for Disruptive Applications W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
58.	Basic and Applied Research at the US Army Combat Capabilities Development Command - Soldier Center W911QY-25-R-0023	The Soldier Center is seeking solutions in the following scientific and technical areas: Combat Feeding & Equipment; Soldier Protection & Survivability; Modeling & Simulation; Human Performance & Biomechanics; Expeditionary Maneuver Support; Aerial Delivery; and Simulation & Training Technology. https://sam.gov/opp/e85e373d22ef47018b0336fc6a258002/view	Dependent upon proposal	Concept papers accepted on a rolling basis until 2/27/30
59.	BAA for Chemical, Biological, Radiological, Nuclear, and Explosive Defense Efforts W911SR-24-R-DEVB	DEVCOM CBC's mission is to provide innovative chemical, biological, radiological, nuclear and explosive (CBRNE) defense capabilities to enable the Joint Warfighters' dominance on the battlefield and interagency defense of the homeland. Mission areas include: Sensor technologies and biomaterials; Biological point detection; Chemical point detection; Early warning and detection; Collective protection; Respiratory protection; Decontamination; CBRN countermeasures; and Chemical biological advanced materials and manufacturing science. https://sam.gov/opp/fca6a4b42ff94fd5892fdae9799941f/view	Dependent upon proposal and award mechanism	Preproposals accepted through 8/20/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BARDA (2)		
60.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/opp/d832248e72e14c3c8cee96ee3c8b2170/view	Dependent upon proposal	Proposal: 9/25/28
61.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	All AOIs are currently closed. No initial awards will be executed. Eligible +Phase submissions will still be accepted and reviewed in accordance the process outlined the EZBAA and corresponding AOI. https://sam.gov/opp/6684d4a2734047d58d6cbf7e5obdd00a/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (3)		
62.	Expedited Research Innovation System (ERIS) DARPA-PS-25-05	DARPA seeks to obtain solutions or capabilities that deliver breakthrough technological advancements that are new as of the date of submission; or technologies, processes, research or methods. Topics include: Advanced technologies for defense against potential chemical and biological threats, human-made or naturally occurring; Advanced technologies for the improved resilience of US operations throughout the prepare, deployment, execute, and return cycle; and Development of groundbreaking methods and metrology for complex, emergent, and adaptive systems, going beyond the limitations of current reductive scientific methods. https://sam.gov/opp/4f1cbdbab2a1433081746c9a7ec01bca/view	Dependent upon proposal and award mechanism	Proposal: 5/30/26
63.	Biological Technologies BAA HR001124S0034	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: AI/ML; Combat Casualty Care; Human Performance; Materials, Sensors, Processing; Agricultural and Environmental; Security, Safety, and Surveillance; and Biomedical and Biodefense. https://sam.gov/workspace/contract/opp/8d403582edfd409795560247e8d229b7/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 9/30/26
64.	Defense Sciences Office, Office-wide HR001125S0013	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Materials, Manufacturing, & Structures; Sensing and Measurement; Math, Computation, and Processing; Complex, Dynamic, and Intelligent Systems. https://sam.gov/opp/c3fobedbf22c4e2daf5bbo713f4ce4a/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 6/2/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY (4)		
65.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E : <ul style="list-style-type: none"> • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/workspace/contract/opp/d5bcd60592c84adf908c5c1ca747bc4e/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
66.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA) HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures. https://www.grants.gov/search-results-detail/353860	Dependent upon proposal and award mechanism	Proposal: 4/28/29
67.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness. https://sam.gov/opp/7a98bf70ac2a49c8b8eod71abbc93750/view	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29
68.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-25-S-0001	Fundamental research efforts enable capabilities such as development of improved detection devices for traditional and nontraditional chemical agents; development of diagnostics for existing and emerging infectious disease threats; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration. https://www.grants.gov/search-results-detail/356612	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2034



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEPARTMENT OF ENERGY (1)		
69.	FY 2026 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003600	SC accomplishes its mission and advances national goals by supporting: The frontiers of science—exploring nature’s mysteries from the study of fundamental subatomic particles, atoms, and molecules that are the building blocks of the materials of our universe and everything in it to the DNA, proteins, and cells that are the building blocks of life. Each of the programs in SC supports research probing the most fundamental disciplinary questions. https://www.grants.gov/search-results-detail/360678	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/26
		NAVY (2)		
70.	FY25 Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001425SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://sam.gov/workspace/contract/opp/oefe2fde0926428f8ecc073f3fc7b5d9/view	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/26
71.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/workspace/contract/opp/f85a428ac9ac46c4a3278e11394c18d9/view	Dependent upon proposal and award mechanism	White papers accepted through 3/31/26
		OFFICE OF THE UNDERSECRETARY OF DEFENSE (1)		
72.	OUSD(R&E) Seeks Advanced Manufacturing, Prototypes and Materials (AMPAM) HQ003425BOTA1	OUSD(R&E)’s goal is to foster increased collaboration and partnership between Government and Industry to identify, develop, and mature new or improved manufacturing and repair processes and bridge the gap between discovery and implementation of new capabilities for the warfighter. Examples may include Bio-manufacturing of medical related material and Bio-manufacturing of materials or products in the supply chain. https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis through 10/2/27
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE		
73.	Engagement Award: Capacity Building -- Spring 2026 Cycle	The Engagement Award: Capacity Building opportunity funds projects that build communities prepared to participate in PCOR/CER. These awards support organizations with strong ties to patients, caregivers, clinicians, and other stakeholders who have a connection to a research focus area and seek to better equip stakeholders to engage as partners in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-spring-2026-cycle	Up to \$300,000, for up to 2 years	Letter of intent: 3/30/26 Proposal: 7/13/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE (7)		
74.	Engagement Award: Dissemination Initiative -- Spring 2026 Cycle	<p>The Engagement Award: Dissemination Initiative funding opportunity aims to support projects that help organizations and communities plan for or actively bring pertinent PCORI-funded research findings to their specific audiences, including relevant patients, clinicians, communities, and others, in ways that will command their attention and interest and encourage use of this information in their healthcare decision making.</p> <p>https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-spring-2026-cycle</p>	Up to \$300,000, for up to 2 years	Letter of intent: 3/30/26 Proposal: 7/13/26
75.	Engagement Award: Stakeholder Convening Support -- Spring 2026 Cycle	<p>The Engagement Award: Stakeholder Convening Support funding opportunity provides support to organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. Convenings should be designed with the active collaboration and partnership of patients, community groups, and/or other stakeholder organizations.</p> <p>https://www.pcori.org/funding-opportunities/announcement/engagement-award-convening-support-spring-2026-cycle</p>	Up to \$125,000, for up to 1 year	Letter of intent: 3/30/26 Proposal: 7/13/26
76.	Forecast: Advancing the Science of Engagement in Research PCORI Funding Announcement -- Cycle 2 2026	<p>This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes of engagement in research; Techniques that lead to effective engagement in research; and How effective engagement techniques should be modified and resourced for different contexts, settings, and communities. It will solicit applications that focus on: Development and validation of measures to capture structure/context, process and outcomes of engagement, for both stakeholders and investigators; and Development and/or testing of engagement methods to generate evidence on the most effective approaches for engagement in research and how effectiveness varies by context.</p> <p>https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-2-2026</p>	Up to \$1.5 million, for up to 3 years	System opens: 4/1/26 Letter of intent: 4/28/26 Proposal: 9/1/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE		
77.	Forecast: Broad Pragmatic Studies Funding Announcement - Cycle 2 2026	<p>PCORI seeks to fund patient-centered CER comparing two or more alternatives, each of which has established efficacy and/or is in widespread use. PCORI is interested in research that fills pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader healthcare community make informed decisions about their health care and health outcomes. Applicants for the 2026 BPS PFA may select up to three of PCORI's Topic Themes; or "Other." Cycle 1 SAEs include: Addressing Obesity; Treatments and Strategies To Address Menopausal Symptoms; and Improving Care Delivery for Individuals With Intellectual and Developmental Disabilities (IDD).</p> <p>https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-pcori-funding-announcement-cycle-2-2026</p>	Up to \$12 million, for up to 5 years Dependent upon award mechanism	System opens: 4/1/26 Letter of intent: 4/28/26 Proposal: 9/1/26
78.	Forecast: Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research PCORI Funding Announcement -- Cycle 2 2026	<p>PCORI seeks to fund projects that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by CER studies. For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in CER; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in CER.</p> <p>https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-2-2026</p>	Up to \$750,000, for up to 3 years	System opens: 4/1/26 Letter of intent: 4/28/26 Proposal: 9/1/26
79.	Forecast: Phased Large Awards for Comparative Effectiveness Research -- Cycle 2 2026	<p>PCORI is interested in research that aims to fill pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader health and healthcare community make informed decisions about their health care and health outcomes. Applicants to the Cycle 1 2026 PLACER PFA may select up to three Topic Themes; or Other.</p> <p>https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-pcori-funding-announcement-cycle-2-2026</p>	Up to \$22 million, for up to 6.5 years	System opens: 4/1/26 Letter of intent: 4/28/26 Proposal: 9/1/26





Terms

AoI: Area of Interest
BAA: Broad Agency Announcement
FOA: Funding Opportunity Announcement
IC: NIH Institutes and Centers
NOFO: Notice of Funding Opportunity
NOSI: Notice of Special Interest
PI: Principal Investigator
RFI: Request for Information
RFP: Request for Proposal
SBIR: Small Business Innovation Research
SDOH: Social Determinants of Health
STTR: Small Business Technology Transfer
TRL: Technology Readiness Level

Agencies

ARPA-H: Advanced Research Projects Agency for Health
ASPR: Administration for Strategic Preparedness and Response
BARDA: Biomedical Advanced Research and Development Authority
CDC: Centers for Disease Control and Prevention
CDMRP: Congressionally Directed Medical Research Programs
DARPA: Defense Advanced Research Projects Agency
DHA: Defense Health Agency
DoD: Department of Defense
FDA: U.S. Food and Drug Administration
MTEC: Medical Technology Enterprise Consortium
NIH: National Institutes of Health
NSF: National Science Foundation
PCORI: Patient-Centered Outcomes Research Institute
USAMRDC: U.S. Army Medical Research and Development Command
USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases
USSOCOM: United States Special Operations Command

GBG Acronyms

Updated Monthly

February 11, 2026

<https://www.g2gconsulting.com/gbg-reporting-service/>

NIH Institutes and Centers

CC: NIH Clinical Center
CIT: NIH Center for Information Technology
CSR: NIH Center for Scientific Review
FIC: Fogarty International Center
NCATS: National Center for Advancing Translational Sciences
NCCIH: National Center for Complementary and Integrative Health
NCI: National Cancer Institute
NEI: National Eye Institute
NHGRI: National Human Genome Research Institute
NHLBI: National Heart, Lung, and Blood Institute
NIA: National Institute on Aging
NIAAA: National Institute on Alcohol Abuse and Alcoholism
NIAID: National Institute of Allergy and Infectious Diseases
NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases
NIBIB: National Institute of Biomedical Imaging and Bioengineering
NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIDA: National Institute on Drug Abuse
NIDCD: National Institute on Deafness and Other Communication Disorders
NIDCR: National Institute of Dental and Craniofacial Research
NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases
NIEHS: National Institute of Environmental Health Sciences
NIGMS: National Institute of General Medical Sciences
NIMH: National Institute of Mental Health
NIMHD: National Institute on Minority Health and Health Disparities
NINDS: National Institute of Neurological Disorders and Stroke
NINR: National Institute of Nursing Research
NLM: National Library of Medicine

Join the private GBG Zoom Meeting:

<https://uso6web.zoom.us/j/83307425123?pwd=MDchzHQotW8vN9bw1SjaviNLwueEPw.1>

Meeting ID: 833 0742 5123

Passcode: 907983

